101 related articles for article (PubMed ID: 20683268)
1. Role of early PET in the management of diffuse large B-cell lymphoma.
Michallet AS; Trotman J; Tychyj-Pinel C
Curr Opin Oncol; 2010 Sep; 22(5):414-8. PubMed ID: 20683268
[TBL] [Abstract][Full Text] [Related]
2. PET/CT for therapy response assessment in lymphoma.
Hutchings M; Barrington SF
J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
[TBL] [Abstract][Full Text] [Related]
3. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Kasamon YL; Jones RJ; Wahl RL
J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
[TBL] [Abstract][Full Text] [Related]
4. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.
Hoppe BS; Moskowitz CH; Zhang Z; Maragulia JC; Rice RD; Reiner AS; Hamlin PA; Zelenetz AD; Yahalom J
Bone Marrow Transplant; 2009 Jun; 43(12):941-8. PubMed ID: 19139730
[TBL] [Abstract][Full Text] [Related]
5. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
6. FDG PET-CT in the management of primary breast lymphoma.
Santra A; Kumar R; Reddy R; Halanaik D; Kumar R; Bal CS; Malhotra A
Clin Nucl Med; 2009 Dec; 34(12):848-53. PubMed ID: 20139815
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET in the clinical management of Hodgkin lymphoma.
Hutchings M; Eigtved AI; Specht L
Crit Rev Oncol Hematol; 2004 Oct; 52(1):19-32. PubMed ID: 15363464
[TBL] [Abstract][Full Text] [Related]
8. Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas: changing the paradigms of treatments?
Coleman M; Kostakoglu L
Cancer; 2006 Oct; 107(7):1425-8. PubMed ID: 16933331
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
11. Use of PET/CT to evaluate response to therapy in lymphoma.
Zanoni L; Cerci JJ; Fanti S
Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):633-47. PubMed ID: 22231583
[TBL] [Abstract][Full Text] [Related]
12. Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?
Mikhaeel NG
Leuk Lymphoma; 2009 Dec; 50(12):1931-6. PubMed ID: 20001245
[TBL] [Abstract][Full Text] [Related]
13. Role of PET in lymphoma.
Gallamini A; Borra A
Curr Treat Options Oncol; 2014 Jun; 15(2):248-61. PubMed ID: 24619427
[TBL] [Abstract][Full Text] [Related]
14. The role of FDG-PET in the interim evaluation of therapy response in diffuse large B-cell lymphoma.
Ellmann A
Transfus Apher Sci; 2013 Aug; 49(1):40-2. PubMed ID: 23769694
[TBL] [Abstract][Full Text] [Related]
15. When should FDG-PET be used in the modern management of lymphoma?
Barrington SF; Mikhaeel NG
Br J Haematol; 2014 Feb; 164(3):315-28. PubMed ID: 24131306
[TBL] [Abstract][Full Text] [Related]
16. Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?
Casasnovas RO; Meignan M; Berriolo-Riedinger A; Itti E; Huglo D; Haioun C; Morschhauser F
Curr Hematol Malig Rep; 2012 Sep; 7(3):193-9. PubMed ID: 22723050
[TBL] [Abstract][Full Text] [Related]
17. The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy.
Coughlan M; Elstrom R
Cancer Imaging; 2014 Nov; 14(1):34. PubMed ID: 25608713
[TBL] [Abstract][Full Text] [Related]
18. Role of positron emission tomography (PET) in the management of lymphoma.
Elgazzar AH; Alenizi EK
Gulf J Oncolog; 2008 Jan; (3):17-23. PubMed ID: 20084793
[TBL] [Abstract][Full Text] [Related]
19. [Diffuse large B cell lymphoma: management in 2012].
Bonnet C; De Prijck B; Lejeune M; Fassotte MF; Van Den Neste E; Beguin Y
Rev Med Suisse; 2012 Aug; 8(351):1582-4, 1586-90. PubMed ID: 22988711
[TBL] [Abstract][Full Text] [Related]
20. Interim FDG-PET Imaging in Lymphoma.
Gallamini A; Zwarthoed C
Semin Nucl Med; 2018 Jan; 48(1):17-27. PubMed ID: 29195613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
